Human CD20 Antibody - Ofatumumab Biosimilar

Human IgG1 monoclonal antibody (mAb) against human CD20

Anti-hCD20-Of-hIgG1 is the biosimilar of the clinical antibody ofatumumab.Anti-hCD20-Of-hIgG1 features the constant region(Fc) of a human IgG1 isotype and the variable region of ofatumumab. Ofatumumab targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.

Ofatumumab is a fully human type I (first generation) monoclonal antibody that mediates B cell destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Ofatumumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL)[1-3].

InvivoGen’s Anti-hCD20-Of-hIgG1 is generated by recombinant DNA technology, produced in Chinese hamster ovary(CHO) cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used to compare several biological activities such as ADCC (see below or in the 'upon request' section).
InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Rituximab or Obinutuzumab, with either native or engineered Fc region.

Read our review on Antibody Isotypes

References:

1. Baig NA. et al., 2014. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 192(4):1620-9.
2. Lin TS., 2010. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 3:51-9.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.